Primary Afferent Nociceptor as a Target for the Relief of Pain by Parada, Carlos A. et al.
Hindawi Publishing Corporation
Pain Research and Treatment
Volume 2012, Article ID 348043, 2 pages
doi:10.1155/2012/348043
Editorial
Primary AfferentNociceptoras a Target forthe Reliefof Pain
CarlosA. Parada,1 ClaudiaH.Tambeli,1 Paul G.Green,2 andBrianE.Cairns3
1State University of Campinas, 13083-862 Campinas, SP, Brazil
2Department of Oral and Maxillofacial Surgery, University of California San Francisco, San Francisco, CA 94143-0440, USA
3Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
Correspondence should be addressed to Carlos A. Parada, caparada@unicamp.br
Received 24 November 2011; Accepted 24 November 2011
Copyright © 2012 Carlos A. Parada et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Primary aﬀerent nociceptors (A-delta and C ﬁbres) are
generally the ﬁrst structures to be involved in the perception
of pain. These specialized primary aﬀerent sensory neurons
have also been described as important to the development
of inﬂammatory and neuropathic pain. Primary aﬀerent
nociceptors are particularly interesting as a target for the
development of new drugs to control pain given the fact
that they are located outside the central nervous system
and separated from it by the blood brain barrier. Although
signiﬁcant advances have been made to better understand
the molecular mechanisms involved in activation of pri-
mary aﬀerent nociceptors, important aspects of this process
remain unclear. In this special issue are papers that address
some of these aspects.
Dr. R. Hulse and colleagues discuss the importance of
galanin and the galanin receptor 2 on primary aﬀerent
neurons as a potential target to control neuropathic pain.
As described by the authors, despite the dramatic increase
of galanin expression in the peripheral nervous system
following nerve injury, few studies have investigated the role
that this neuropeptide plays in modulating nociception at
the level of the primary aﬀerent nociceptor. It is important
to highlight that the most widely used medicines to con-
trol neuropathic pain include anticonvulsants (antiseizure
medications) and antidepressants and that these agents are
usually used for central nervous system disorders. As a
result, these therapies for neuropathic pain are associated
with signiﬁcant central nervous system side eﬀects, such as
drowsiness, dizziness, and cognitive deﬁcits. Therefore, the
ﬁndingofincreasedexpressionofgalanininprimaryaﬀerent
nociceptors could emerge as an interesting peripheral target
to control neuropathic pain that might be devoid of prob-
lematic central nervous system side eﬀects.
Dr. V. Chaban summarizes the role that estrogen plays
in visceral nociception at the level of primary sensory
neurons. This review paper reports that the incidence of
persistent, episodic, or chronic “functional” visceral pain
associated with disorders such as irritable bowel syndrome,
ﬁbromyalgia, painful bladder syndrome, chronic pelvic pain,
and others is much more prevalent in women than in men.
Based on this observation, the author hypothesizes that
viscerovisceral cross-sensitization is mediated by estrogen
modulation of the response of dorsal root ganglion neurons
to adenosine triphosphate (ATP). This estrogen-mediated
modulation of visceral aﬀerent nociceptors may also explain
the observed clinical and animal sex-related diﬀerences in
visceral hypersensitivity.
Dr. Y. Tousignant-Laﬂamme and Dr. S. Marchand hy-
pothesize that aging, independent of the hormonal status,
changes pain responses in young postmenopausal women.
They tested this hypothesis by examining pain responses
to diﬀerent experimental nociceptive stimuli in a group of
young postmenopausal women and compared the results to
nonmenopausal women. They undertook these experiments
while the nonmenopausal women were menstruating, since
sex hormone levels are at their lowest during menses. Blood
sampling enabled them to assure that both groups had com-
parable sex hormones levels for progesterone and estrogen,
the main female sex hormones. The authors concluded that
age seems to be the main factor inﬂuencing changes in tonic
pain perception in the group of midlife postmenopausal
women.Theyalsosuggestedthatareductionofthepeakpain
intensity in the postmenopausal women was probably due to
a reduction of function in myelinated Aδ ﬁbers that occurs
naturally with age.2 Pain Research and Treatment
Dr. Y.-H. Jin and colleagues hypothesize that glutamate
is released in peripheral tissues following activation of the
TPRV1 receptors. This increase in peripheral glutamate then
acts on glutamate receptors on primary aﬀerent nociceptor
terminals to activate nociceptors. They tested this hypothesis
by measuring c-Fos expression in the spinal cord following
injection of capsaicin alone (to activate TRPV1 receptors)
and capsaicin with various glutamate receptor antagonists.
Neuronal c-Fos expression was signiﬁcantly increased by
capsaicin,andthiseﬀectwasantagonizedwhencapsaicinwas
coadministered with glutamate receptor antagonists. Based
on the eﬀectiveness of the diﬀerent glutamate antagonists
used, the authors conclude that glutamate receptors are
present on peripheral terminals of primary aﬀerent noci-
ceptors and that activation of these ionotropic glutamate
receptors mediate hyperalgesia produced by activation of
TRPV1.
Dr. K. E. Miller and colleagues describe ﬁndings of an
increase in the enzyme glutaminase in primary aﬀerent sen-
sory neurons during inﬂammation. They hypothesize that
elevated glutaminase action in primary aﬀerent nociceptor
cell bodies could produce increased glutamate synthesis in
the peripheral and spinal terminal endings of these neurons.
This increase in glutaminase activity may contribute to the
mechanisms that underlie central sensitization and may
also provide a potential target for novel therapies for the
treatment of chronic pain.
The paper by M. Gautam and colleagues examines the
underlying mechanism of pain in a model of long-lasting
mechanical hyperalgesia that employs repeated injections
of a low-pH solution into the gastrocnemius muscle at 5-
day intervals. One unanswered question about this model
is whether the hyperalgesia is mediated by a long-term
alteration in the expression and/or response properties of
acid-sensing ion channels (ASICs) on muscle nociceptors.
Theirpapercombinedwholecellpatchclampandbehavioral
testing to determine whether long-term changes in the
properties of peripheral ASICs contribute to the mechanical
hyperalgesia seen in this model. The authors conclude
that ASICs are not involved in long-term maintenance of
hyperalgesia in this model.
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